Hot Topics

All Related Stories

• 

  India's drug patent rejection: What does it mean for drugmakers?

  The India Supreme Court's rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world's largest drugmakers. The ruling, which was handed down on Monday, signals the latest shift in the world of drug development in emerging markets such as India and Brazil, where drugmakers have been looking for growth.

• 

  India's top court to rule on landmark drug patent case

  India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies that say they should be allowed to continue producing cheaper generic versions of many lifesaving medicines.

• 

  India rejects Bayer plea against cheap cancer drug

  India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive lifesaving medicines to the poor.

• 

  Provinces, territories' plan to buy generic drugs in bulk could save $100 million

  In an effort to save millions in drug costs, nine provinces and all three territories are working together to bulk buy six of the highest-selling generic drugs. Under the plan, the drugs would be purchased at 18 per cent of their brand-name counterparts, compared to the current 25 to 40 per cent.

• 

  Court to decide fate of cheap, generic drugs used by poor

  From Africa's crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will determine whether India's drug companies can continue to provide cheap versions of many life-saving medicines.

• 

  Defective generic pill revives quality concerns

  More Americans than ever are taking generic drugs, as blockbuster medicines like Plavix and Lipitor become available in low-cost versions. But the government's revelation this week that it mistakenly approved a defective generic antidepressant could stoke longtime concerns about the quality of knockoff drugs